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Abstract Pharmacogenetic tests allow medications to be
tailored to individual patients to improve efficacy and
reduce drug toxicity. In 2005, the International Society of
Pharmacogenomics (ISP) made recommendations for
undergraduate medical teaching in pharmacogenetics. We
aimed to establish the quantity and scope of this in British
medical schools. An electronic survey was sent to all
British medical schools. Nineteen out of 34 (56%) medical
schools responded. Sixteen of the 19 (84%) respondents
provided pharmacogenetics teaching, usually 1–2 h in
total. Only four (21%) medical schools offered the four or
more hours of teaching recommended by the ISP. How-
ever, 10 of 16 (63%) schools felt the amount of
pharmacogenetic teaching offered was sufficient. The
quantity of undergraduate teaching of pharmacogenetics is
low. However, a majority of UK medical schools teach it,
covering a broad scope of elements. It is encouraging that
future clinicians are being provided with the knowledge to
deliver pharmacogenetics into clinical practice.
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Introduction
Pharmacogenetic tests allow medicines to be tailored to
individual patients. There are a growing number of
examples of pharmacogenetic tests used in clinical practice
(Lesko 2007; Giacomini et al. 2007). They potentially
allow identification of individuals in whom a particular
treatment is likely to be effective or avoidance of this
treatment in those who have an increased chance of a life-
threatening adverse reaction to a particular medication.
Although pharmacogenetic tests are currently only useful
to a minority of patients, it is likely that they will influence
clinical practice to a greater extent in the future (Lesko
2007; Giacomini et al. 2007). For example, the USA Food
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and Drug Administration (FDA) now recommends, but does
not mandate, testing for single nucleotide polymorphisms
(SNPs) in the 2C9 isoform of cytochrome P450 (CYP2C9)
and vitamin K epoxide reductase complex subunit 1
(VKORC1) prior to prescribing warfarin in order to detect
patients at increased risk of haemorrhage (Gage and Lesko
2008). Testing for VKORC1 and CYP2C9 variants, used
with other clinical information, is particularly valuable to
determine the correct dose at the start of treatment (Flock-
hart et al. 2008). In the UK, adoption of pharmacogenetic
testing has increased for a few indications within the last
5 years, with the routine testing of thiopurine methytrans-
ferase (TPMT) activity prior to thiopurine use and HLA-
B*5701 typing prior to abacavir use in patients with HIV
now standard practice (Newman and Payne 2008).
A recent qualitative survey of patient preferences con-
cluded that patients would prefer pharmacogenetic testing
to be integrated into their management plan by the medical
team looking after their specific condition (Fargher et al.
2007). This requires that healthcare professionals, in all
disciplines where pharmacogenetic testing is or will be
available, are familiar with the tests’ interpretation and
sufficiently confident to explain and incorporate the results
into each patient’s management. However, at present, most
doctors do not feel that they have the responsibility, time or
capacity to provide and interpret genetic tests (Fargher
et al. 2007). Clearly, inadequate education both at under-
graduate and postgraduate levels is a potential barrier to the
widespread uptake of pharmacogenetic tests (Baars et al.
2005; Newman and Payne 2008). In 2005, the International
Society of Pharmacogenomics (ISP), recognizing this
unmet need, published a number of recommendations,
including one for undergraduate medical teaching of
pharmacogenetics (Gurwitz et al. 2005). They proposed
that ‘‘basic MD pharmacogenomics education should ide-
ally encompass at least 4 h, and ideally about 8 h of
teaching’’. These figures were primarily based on the
teaching experience of one of us (DG), who was the lead
author on the ISP recommendations manuscript (Gurwitz
et al. 2005) and who has been teaching pharmacogenetics
to medical students at the Tel-Aviv University medical
school since 2001 (Gurwitz et al. 2003). There it has been
found that 4 h of teaching were the minimum required for
good coverage of the most important clinical aspects of
pharmacogenetics. The ISP has proposed that the teaching
should encompass basic elements on genetic variation,
including polymorphic alleles of key drug metabolising
enzymes and drug transporters affecting drug response and
the potential of pharmacogenetics to improve the quality
and safety of prescribing practice. Clinical examples of
pharmacogenetics in current usage should also be included.
Therefore, between September and November 2008, we
carried out a survey of British Medical Schools aiming to
assess the amount and type of pharmacogenetic teaching
currently offered and to establish to what extent the ISP
recommendations had been adopted.
Methods
Survey design
The questionnaire was designed using the free internet
software ‘Qualtrics’ (http://qtrial.qualtrics.com).
The questionnaire included 16 questions in total (see in
full at supplementary information); questions that were not
relevant given the preceding answer were automatically
skipped. Information regarding the amount and type of
pharmacogenetics teaching offered and attitudes to phar-
macogenetics was sought.
Survey distribution
The survey was sent by email to a nominated primary
contact for each Medical School, which was identified by
The Higher Education Academy Subject Centre for Med-
icine, Dentistry and Veterinary Medicine.
The primary contact was invited to identify the appropriate
staff member with responsibility for pharmacogenetics
teaching to respond to the survey. Attached to the initial
contact email was a covering letter describing the purpose of
the questionnaire and an article describing the ISP recom-
mendations for pharmacogenetics8 (8 should be available in
Supplementary information). One reminder email was sent
after 2 weeks.
A subset of eight non-responding medical schools was
contacted to identify the reasons for not completing the
survey.
Results
Nineteen of the 34 (56%) medical schools contacted
completed the survey. The reason for non-response given
by eight of the eight medical schools contacted was lack of
time. Two reported that finding out the relevant informa-
tion was time consuming. Where problem based learning
(PBL) was a major component of the teaching, two
responders commented that precisely what was studied by
the students was difficult to determine.
Amount and type of pharmacogenetics teaching
currently offered
Sixteen of the 19 (84%) respondents had pharmacogenetic
teaching in the curriculum. Of the 14 respondents, who
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answered the question, nine provided 1–2 h during the
medical degree, compared to one school which had \1 h,
three with 4–8 h and one providing 8–12 h (Fig. 1).
Eleven medical schools had questions on pharmacoge-
netics in the medical student examination. The elements
of pharmacogenetics covered in the curricula are sum-
marised in Fig. 2. One medical school that used
predominantly PBL, commented that it was not possible
to determine precisely what was learnt, as the students
could choose their own topics based on the cues within
the PBL case.
Pharmacogenetics teaching was provided as lectures by
14 respondents to this question, with some schools sup-
plementing this with PBL (n = 4), case led studies
(n = 3), seminars (n = 3) or computer based learning
opportunities (n = 2) (Fig. 3). The pharmacogenetics
teaching was provided in pharmacology modules (8 of 16),
with other schools providing it in both genetics and phar-
macology modules (n = 2) or as part of integrated learning
or specialist modules. No school provided pharmacoge-
netic teaching exclusively within the genetics curriculum.
Six medical schools had student feedback on pharma-
cogenetics teaching; however, none of the respondents
were aware of the opinions of the students concerning their
pharmacogenetics education.
Ten of the 16 (63%) medical schools with pharmaco-
genetics teaching felt that they offered a sufficient amount,
whereas six (37%) felt this area could be improved on with
more in-depth teaching or improved integration into the
rest of the course. Two medical schools commented that
pharmacology teaching in general was a weak area and
needed improvement:
‘‘[Pharmacogenetics] content OK when compared to
content of rest of pharmacology teaching in curriculum
which is not great’’.
Of the three schools that did not offer pharmacogenetics
teaching, one felt that this area was not relevant to the type
of course they offered and two felt that there wasn’t enough
time to include this area in the curriculum without
excluding something else.
‘‘There is a massive restraint on the period of teaching
for each module and we have several areas of pharmacol-
ogy we would wish to expand. Indeed, some we would
consider more important than the current call.’’
However, one school currently without pharmacoge-
netics teaching thought it should be introduced, despite
time constraints, because ‘‘it may potentially become a
central criterion for rational prescribing.’’
Six (32%) responders felt that pharmacogenetics was
likely to become more important in the future. However,
Fig. 1 Hours of
pharmacogenetics teaching
(number of respondents 14)
Fig. 2 Pharmacogenetics topics covered by the medical schools (number of respondents 16)
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the barriers to teaching this subject are summarised by the
following respondent’s comment:
‘‘The application of pharmacogenomics has progressed
less rapidly than predicted. Given the overcrowding of the
undergraduate medical curriculum, there are problems
implicit in devoting 4–8 h to teaching knowledge which
may not be core until a few years after students have
graduated’’.
Table 1 provides a summary of the general feedback
from medical schools about current pharmacogenetics
teaching.
Discussion
The lack of adequate health care professional education
and the lack of patient education are just two of the
potential barriers to the adoption of pharmacogenetic
testing (Baars et al. 2005; Newman and Payne 2008). This
was also one of the key conclusions of a recent European
Commission Joint Research Centre Report on pharmaco-
genetics and pharmacogenomics (Zika et al. 2006). To
address the future professional need at an undergraduate
level, one of the ISP education forum’s recommendations
was that a minimum of 4 h of undergraduate pharmaco-
genetic teaching should be provided to medical students
(Gurwitz et al. 2005). Whether the recommendations have
been implemented in the UK has not been investigated.
From our survey, it is encouraging to discover that phar-
macogenetics teaching is provided in over 80% of the
medical schools that responded. It is possible that schools
responding to the survey were more likely to offer teach-
ing, but our follow up survey of non-responders does not
support this potential concern. Also the number of UK
medical schools providing pharmacogenetics teaching
mirrors the 78% of pharmacy schools in the US providing
teaching to pharmacists in a survey undertaken in 2004
(Latif 2005). It is sometimes difficult to fully establish all
Table 1 Additional feedback on pharmacogenetics/pharmacogenomics
teaching
Understanding of disease susceptibility and treatment response is
changing rapidly given advances in biomedicine in general.
Doctors need to be much more aware of these developments and
their incipient impact on medical practice
Content OK when compared to content of rest of pharmacology
teaching in curriculum, which is not great
This questionnaire does not really work for our integrated programme
I can only really speak for the clinical course, and I am sure there are
aspects of pharmacogenetics that are covered in the preclinical
years, in both genetics and pharmacology, although I do not have
this detailed information. In the clinical years we concentrate on
teaching pharmacogenetics in the context of therapeutics, so where
there are examples that can readily demonstrate its uses
In terms of their needs for F1 prescribing, I think the current amount
of teaching in pharmacogenetics/pharmacogenomics I give is
probably sufficient. In 2007 I also set an integrative assignment on
pharmacogenetics/pharmacogenomics for students doing a
BMedSci in clinical pharmacology
Likely to gain in prominence
It is difficult to answer these questions in what is a student centred,
self-directed PBL course. There are triggers within the PBL
scenarios to some of the issues but the individual student will
decide to what depth they need to explore so it is difficult to
estimate ‘teaching’ of this subject in the traditional sense and we
can only give estimates of learning. The nature of a PBL course
should be such that students develop the skills of being able to find
out what they need to know when they need to know it. They
should also be searching in the most up to date evidence and thus
should be meeting the areas you describe
We focus on the practical reality of PG and its impact on PD. Much of
the impact that PG will make on prescribing remains aspirational
rather than a reality with the exception of a few key drugs and
ethnic groups. We introduce students to these issues. We do not
examine students in a specific PG paper/questions but integrate
such topics into more general clinically focussed assessments
I believe the report is correct to point out the importance of this.
However, we already have modules and associated classes
beginning at 08:00. To implement effective learning would require
sacrifice elsewhere. I would be interested in information that could
allow the students to attain at least the basics, but further expansion
may be impossible
Fig. 3 Types of
pharmacogenetics teaching
(number of respondents 15)
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of the opportunities available to students in a medical
school as teaching occurs over a long time frame; in many
settings (university, ward-based, computer), and with many
individuals teaching in formal and ad hoc situations.
Therefore, it is possible that this survey underestimates the
amount and extent of pharmacogenetics teaching to UK
medical students.
It is of interest that only four of the 14 responding
schools (29%), offering pharmacogenetics teaching, met
the ISP recommended quantity of four or more hours.
However, the scope of teaching, with most schools
including the major elements proposed by the ISP, suggests
that the core areas of pharmacogenetics are being addres-
sed. Furthermore, only six schools felt that increased
teaching of pharmacogenetics was warranted. The major
concern expressed, regarding increased teaching in phar-
macogenetics, would be the deleterious effect that this
might have on other areas of the curriculum and the
competing interests of other subject elements to be inclu-
ded in the course. However, a number of resources are
already available to assist in developing a pharmacoge-
netics course relevant to medical students (Brazeau and
Brazeau 2006; The National Genetics Education and
Development Centre).
What medical students think about pharmacogenetics
and the education they receive on this topic is not clear.
Most medical schools did not have student feedback on this
topic and those that did, were not sure what their opinions
were. This is particularly pertinent as an assessment of a
pharmacogenetics course for pharmacists in the US found
that many students thought pharmacogenetics was not
relevant to the current practice of pharmacy and evaluated
the course more favourably when specific examples of
applications and future developments were highlighted
(Latif 2005). Clearly, the high use of practical examples in
medical student teaching should address this concern.
In summary, the number of pharmacogenetic tests in
clinical use is likely to increase considerably over the next
decade. At present most testing is provided by specialist
clinicians in oncology, HIV medicine and by physicians
using immunomodulators. Future pharmacogenetic tests
are likely to be relevant to primary care physicians and
potentially available at the point of care. It is vital that all
doctors are aware of the potential and impact of this
technology and that they have the knowledge base to
implement it in the clinical care of their patients. UK
medical schools are providing a core competency in
pharmacogenetics, which must be encouraged and sup-
ported and allowed to develop to mirror its increased
clinical application.
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